RFA-HL-22-002: Lung Transplant Consortium - Clinical Centers (U01 - Clinical Trial Not Allowed)
Closed
This grant is closed. Who won this program's grants before is below, and similar open grants are at the end of the page. It is in our archive of National Institutes of Health notices from 2021.
National Institutes of Health offered grants of up to $275,000 to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. Applications closed on June 15, 2021.
From the official notice on Grants.gov, last changed February 25, 2021. Checked November 7, 2026.
- Award ceiling$275,000
- Cost sharingNot required
- Funding typeCooperative Agreement
About this NIH notice
- Activity codeU01
- Clinical trialsNot allowed
- Funded byNHLBI
- Median yearly award$422,929
- Typical project length5 years
- U01, Research Project Cooperative Agreement. Like an R01, but NIH staff are substantially involved in the work. Other open U01 notices.
Projects funded under RFA-HL-22-002 were run by National Heart Lung and Blood Institute (NHLBI, 7 projects). Contact the program officer at the institute that fits your project before you apply; the notice lists them.
Application due dates, page limits and budget limits are set in the notice. Read RFA-HL-22-002 in the NIH Guide.
Key dates
| Posted | February 25, 2021 |
|---|---|
| Deadline | June 15, 2021 |
| Archived by Grants.gov | July 21, 2021 |
Who can apply
This opportunity was open to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses.
All 15 applicant types the notice lists
- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and State controlled institutions of higher education
- Native American tribal governments (Federally recognized)
- Public housing authorities/Indian housing authorities
- Native American tribal organizations (other than Federally recognized tribal governments)
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Private institutions of higher education
- For profit organizations other than small businesses
- Small businesses
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.
Is this a realistic fit?
- Projects NIH funded under this notice had a median yearly award of $422,929; it allows up to $275,000 per award.
- Most of the program's money (59% over five years) went to nonprofits.
- No cost sharing or match is required.
What the grant funds
This Funding Opportunity Announcement (FOA) seeks applications from lung transplant clinical centers (CCs) to form a cooperative multi-site Lung Transplant Consortium (LTC). The LTC will support CCs in conducting observational and complementary mechanistic clinical research studies that aim to understand the impact of site-specific lung transplant selection criteria and clinical management strategies on donor lung utilization and/or early post-transplant outcomes such as the development of primary graft dysfunction (PGD) and acute lung allograft dysfunction (ALAD) in recipients. Each CC application must consist of a multidisciplinary investigative team that includes a lung transplant surgeon and a lung transplant pulmonologist, and be comprised of primary and subsites that have a combined annual lung transplant volume of at least 100 transplants. Each CC application should propose hypothesis-driven scientific questions to assess certain donor and/or recipient clinical practices and their impact on donor lung utilization, PGD, ALAD or other relevant short-term outcomes that can be addressed through observational data and/or biospecimen collection and analysis at the sites included in their application. In addition, the CCs will be expected to enroll participants and contribute to a core set of data and biospecimens to be collected across all participating consortium sites through the implementation of a common research protocol under the auspices of a centralized Data Coordinating Center (DCC) and a Steering Committee (SC). By leveraging this shared longitudinal resource, LTC investigators will have the tools to identify and answer additional important research questions involving lung transplantation. This FOA runs in parallel with a separate FOA that invites applications for the LTC Data Coordinating Center, solicited under RFA-HL-22-003.
Funded under RFA-HL-22-002 so far
NIH funded 7 projects under RFA-HL-22-002 in fiscal 2022 to 2026, at 7 institutions. The median yearly award was $422,929.
| Project | Institution | Fiscal year | Award |
|---|---|---|---|
| Peri-operative factors that drive cell-free hemoglobin-mediated primary graft dysfunction | Vanderbilt University Medical Center | 2026 | $450,576 |
| The impact of body composition on peri-operative and patient-centered outcomes in lung transplantation. | University of California, San Francisco | 2026 | $418,486 |
| Clinical and Biological Factors Predicting Lung Transplant Textbook Outcomes (U01) | Duke University | 2026 | $370,073 |
| The Clinical and Molecular Impacts of Lung Primary Graft Dysfunction | University of Pittsburgh at Pittsburgh | 2026 | $429,536 |
| Lung transplant recipient exosome phenotypes and the risk of primary graft dysfunction and acute lung allograft dysfunction | University of Washington | 2026 | $413,561 |
| Vaccination responses in lung transplant recipients | Stanford University | 2026 | $409,529 |
| CATCH: Creating Access to Transplant for Candidates who are High Risk | University Health Network | 2026 | $390,726 |
Who has won Lung Diseases Research grants before
From fiscal 2021 to 2025, Lung Diseases Research (93.838) awarded $8.7 million across 5 grant awards, an average of $1.7 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| The General Hospital Corporation | Massachusetts | 1 | $5.4 million |
| New England Research Institutes Inc | Massachusetts | 1 | $2.7 million |
| The Trustees of the University of Pennsylvania | Pennsylvania | 1 | $355,699 |
| University of Washington | Washington | 1 | $350,272 |
| The Trustees of Columbia University in the City of New York | New York | 1 | $319,659 |
Applying now
This notice no longer takes applications. Agencies often post the same opportunity again under a new number, so check the program's notices on Grants.gov and the similar open grants below.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is RFA-HL-22-002 still open?
No. It closed on June 15, 2021.
Who can apply for Lung Transplant Consortium - Clinical Centers (U01 - Clinical Trial Not Allowed)?
National Institutes of Health accepted applications from nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. The notice adds further conditions, so read its eligibility section.
What is the deadline for Lung Transplant Consortium - Clinical Centers (U01 - Clinical Trial Not Allowed)?
Closed June 15, 2021. Applications are no longer accepted; the program's newer notices are on this page when there are any.
How much funding is available?
Awards of up to $275,000 each.
Who has been funded under RFA-HL-22-002?
NIH RePORTER lists 7 projects funded under RFA-HL-22-002 in fiscal 2022 to 2026, at 7 institutions. The most were at Vanderbilt University Medical Center, University of California, San Francisco, Duke University.
Who has won Lung Diseases Research grants before?
The largest recipients over five fiscal years were The General Hospital Corporation, New England Research Institutes Inc, The Trustees of the University of Pennsylvania. The program made 5 awards worth $8.7 million in that time.
Similar open grants
- Single Source for the Continuation of the Caring for OutPatiEnts after Acute Kidney Injury (COPE-AKI) Scientific and Data Research Center (U01 Clinical Trial Required)
- Single Source for the Continuation of the Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Center (Collaborative U01 Clinical Trial Not Allowed)
- Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)
- Single Source for the Continuation of the Physiology of the Weight Reduced State (POWERS) Study (U01- Clinical Trials Required)
- Canine Cancer Immunotherapy Network (K9CIN; U01 Clinical Trial Not Allowed)
- Opportunities for Collaborative Research with the NIH Intramural Research Program (U01 Clinical Trial Optional)